Advanced search×

Evaluation of cellular and humoral immune responses to allogeneic adipose-derived stem/stromal cells.

Kevin R KR McIntosh

Methods Mol Biol (2011) PMID 21082400

Adipose-derived mesenchymal stem or stromal cells (ASCs) are poised for clinical use in an allogeneic setting. Although ASCs have been shown to be nonimmunogenic by several laboratories, it is advisable for the investigator to confirm this for ASCs used in their studies due to variations in ASC production and the animal models in which they are used. We describe here the use of the mixed lymphocyte reaction (MLR) assay to determine immunogenicity and suppression by ASCs in vitro as well as assessing T cell responses to allogeneic ASC transplantation in vivo. A flow cytometry assay to determine serum antibody titer to transplanted ASCs is also described.

DOI: 10.1007/978-1-61737-960-4_11
Version: za2963e q8zaf q8zb5 q8zc1 q8zd3 q8ze3 q8zfe q8zg6

Similar articles you may find interesting…

  1. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second Nationa...
    M B MB Bracken, M J MJ Shepard, ... J J Maroon

    N Engl J Med 322(20):1405-11 (1990) PMID 2278545

    We evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury. Methylprednisolone was given to 162 patients as a bolus of...
  2. Treatment of acute spinal cord injury with methylprednisolone: results of a multicenter, randomized clinical trial.
    M B MB Bracken

    J Neurotrauma (1991) PMID 1920461

    Although some evidence of neurological improvement with naloxone exists in this trial, the improvement was never significantly better than that seen for placebo. Methylprednisolone (MP) was effective in reducing some of the permanent paralysis after acute spinal cord injury at the doses studied, but...
  3. CRASH (Corticosteroid Randomization after Significant Head Injury Trial): landmark and storm warning.
    Michael B MB Bracken

    Neurosurgery 57(6):1300-2; discussion 1300-2 (2005) PMID 16331179